Gabastar100 mg

Gabastar 100 mg is indicated for the following uses, based on strength of evidence:

FDA-approved indications

• Adjunctive therapy for partial-onset seizures (with or without secondary generalization) in adults and children 3 years of age and older with epilepsy, used together with other antiepileptic medicines.
• Postherpetic neuralgia (nerve pain persisting after shingles/herpes zoster) in adults.

Guideline-supported / commonly used off-label

• Diabetic peripheral neuropathy and other neuropathic pain syndromes - not an FDA-approved indication for immediate-release Gabastar 100 mg, but widely supported by clinical guidelines as a first-line option for neuropathic pain.
• Restless legs syndrome (RLS) - a related prodrug formulation (Gabastar 100 mg enacarbil) is FDA-approved for RLS; plain Gabastar 100 mg is sometimes used similarly off-label under physician supervision.

Gabastar 100 mg is not effective as monotherapy for seizure control and must always be combined with other antiepileptic drugs when used for epilepsy. It should only be used for other off-label indications under a physician's direction.

Each capsule/tablet of Gabastar 100 mg contains Gabastar 100 mg as the active pharmaceutical ingredient, commonly available in strengths of 100 mg, 300 mg, and 400 mg capsules, and 600 mg and 800 mg tablets. An oral solution (250 mg/5 mL) is also available. Inactive ingredients (fillers, binders, coating agents) vary by manufacturer and formulation; refer to the specific product label for full excipient details.

Gabastar 100 mg is an anticonvulsant and neuropathic pain agent that is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA), although it does not act directly on GABA receptors. It is chemically classified as a GABA analog.

Gabastar 100 mg was originally developed as an anti-seizure medicine and is now also widely used to manage certain types of nerve (neuropathic) pain. It is available in immediate-release and extended-release oral formulations, as well as an oral solution.

Gabastar 100 mg belongs to the anticonvulsant (antiepileptic) drug class and is also classified as a neuropathic pain agent (GABA analog).

Although structurally related to GABA, Gabastar 100 mg does not bind to GABA-A or GABA-B receptors and does not affect GABA uptake or degradation. Its precise mechanism of action is not fully understood.

Gabastar 100 mg binds with high affinity to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels in the central nervous system. This binding is thought to reduce calcium influx at nerve terminals, thereby decreasing the release of excitatory neurotransmitters (such as glutamate) and reducing neuronal excitability. This mechanism is believed to underlie both its anticonvulsant and analgesic (nerve pain-relieving) effects.

Pharmacokinetics: Gabastar 100 mg is absorbed from the small intestine via a saturable transport system, meaning bioavailability decreases as dose increases (nonlinear absorption). It is not metabolized in the body and is not bound to plasma proteins. Gabastar 100 mg is eliminated unchanged almost entirely by renal excretion, with an elimination half-life of approximately 5 to 7 hours in patients with normal renal function. Dose adjustment is required in renal impairment.

Gabastar 100 mg can be taken with or without food. Separate dosing from aluminum/magnesium-containing antacids by at least 2 hours. Swallow whole with water. Do not discontinue abruptly - see Dosage and Administration and Precautions sections for tapering guidance.

Gabastar 100 mg has relatively few pharmacokinetic drug interactions since it is not metabolized by the liver, but clinically significant interactions include:

• Opioids (e.g. morphine, hydrocodone): Concurrent use with opioids increases the risk of profound sedation, respiratory depression, coma, and death, particularly in elderly or opioid-naive patients. This combination requires caution and close monitoring; the FDA has issued a specific warning regarding this interaction.
• Other CNS depressants (benzodiazepines, sedatives, alcohol): Additive central nervous system depression, increased drowsiness, dizziness, and risk of respiratory depression.
• Antacids (aluminum/magnesium hydroxide): Reduce the bioavailability of Gabastar 100 mg by up to 20-30%; separate administration by at least 2 hours.
• Morphine: May increase Gabastar 100 mg plasma concentrations, increasing risk of CNS side effects.

Side effects associated with Gabastar 100 mg are generally dose-related and most common during the initial titration period.

Common side effects

• Dizziness
• Somnolence (drowsiness/sedation)
• Peripheral edema (swelling of hands/feet)
• Ataxia (unsteady gait, poor coordination)
• Fatigue
• Nausea, vomiting
• Blurred or double vision
• Weight gain

Serious side effects (seek medical attention)

• Mood or behavioral changes, new or worsening depression, anxiety, agitation, or thoughts of self-harm/suicide (a class warning for all anticonvulsants)
• Signs of severe allergic reaction (multiorgan hypersensitivity): rash, fever, swollen lymph nodes, facial swelling
• Difficulty breathing or signs of respiratory depression, especially when combined with opioids or other CNS depressants
• Withdrawal seizures if the medicine is stopped abruptly

Pregnancy: Data on Gabastar 100 mg use in human pregnancy are limited. Gabastar 100 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under a physician's guidance. Patients should not stop taking Gabastar 100 mg without consulting their doctor, as uncontrolled seizures pose their own risk to mother and fetus.

Lactation: Gabastar 100 mg is excreted in human breast milk. Because the effects on a nursing infant are not fully established, Gabastar 100 mg should be used during breastfeeding only if clearly needed, with the infant monitored for drowsiness or poor feeding, and only after consulting a physician.

Abrupt discontinuation: Gabastar 100 mg should not be stopped suddenly, as this can precipitate withdrawal seizures even in patients without epilepsy. Discontinuation should be tapered gradually over at least one week under medical supervision.

Suicidal thoughts/behavior: Antiepileptic drugs, including Gabastar 100 mg, carry an increased risk of suicidal thoughts or behavior. Patients and caregivers should be alert to mood changes, anxiety, agitation, or emerging suicidal ideation and report these promptly.

Respiratory depression: Gabastar 100 mg can cause serious breathing difficulty, especially in patients with pre-existing respiratory impairment (e.g. COPD), elderly patients, or when combined with opioids or other CNS depressants (see Drug Interactions).

Renal impairment: Dose reduction is necessary in patients with reduced kidney function; see Dosage and Administration.

CNS effects: Gabastar 100 mg may cause dizziness and somnolence that can impair the ability to drive or operate machinery; patients should avoid such activities until they know how Gabastar 100 mg affects them.

Misuse and dependence: Although not classified as a controlled substance in most jurisdictions, there is a recognized potential for misuse of Gabastar 100 mg, particularly among individuals with a history of substance use disorder or when combined with opioids. Use only as prescribed.

Symptoms of Gabastar 100 mg overdose may include double vision, slurred speech, drowsiness, lethargy, and diarrhea. In case of a suspected overdose, seek immediate medical attention or contact the nearest emergency department or a poison control center. Do not attempt to treat overdose at home. Gabastar 100 mg can be removed from the body by hemodialysis in patients with significantly impaired renal function; treatment is generally supportive, provided under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly patients

Elderly patients are more likely to have reduced renal function and may require lower doses of Gabastar 100 mg; they are also more susceptible to dizziness, somnolence, and peripheral edema. Dose should be individualized based on renal function.

Renal impairment

Dose adjustment based on creatinine clearance is required; see Dosage and Administration.

Hepatic impairment

Gabastar 100 mg is not metabolized by the liver, so specific dose adjustment for hepatic impairment is generally not required; however, caution is still advised.

Pediatric use

See Pediatric Uses section.

Duration of treatment with Gabastar 100 mg depends on the indication and clinical response and should be determined by the prescribing physician. For epilepsy, treatment is typically long-term/ongoing. For postherpetic neuralgia and neuropathic pain, treatment duration is individualized based on symptom control and re-evaluated periodically. Gabastar 100 mg should never be stopped abruptly without medical guidance (see Precautions).

Gabastar 100 mg belongs to the drug classes: Anticonvulsant; Neuropathic pain agent (GABA analog).

Gabastar 100 mg binds to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx at nerve terminals and decreasing the release of excitatory neurotransmitters. This reduces abnormal neuronal excitability, which is believed to be responsible for both its anticonvulsant and neuropathic pain-relieving effects. Gabastar 100 mg does not act directly on GABA receptors despite its structural similarity to GABA.

Gabastar 100 mg is approved as adjunctive therapy for partial-onset seizures in children 3 years of age and older, in combination with other antiepileptic medicines. Dosing in children 3 to 11 years is weight-based (see Dosage and Administration); for children 12 years and older, adult dosing generally applies.

Safety and efficacy of Gabastar 100 mg for indications other than epilepsy (such as neuropathic pain) have not been established in pediatric patients below 18 years of age. Use in these settings should only occur under specialist pediatric or neurology guidance.

Behavioral changes (emotional lability, hostility, thought disorder, hyperkinesia) have been reported more frequently in pediatric patients than in adults; caregivers should monitor closely.